The Texas A&M Center for Innovation is an integrated and comprehensive solution that will guarantee the availability of an effective U.S. response to any attack or threat, known or unknown, including a novel, previously unrecognized, naturally occurring emerging infectious disease.

The Center is founded on an initial $285.6 million public-private partnership with the U.S. Department of Health and Human Services designed to enhance the nation’s emergency preparedness by providing surge capacity for pandemic influenza vaccines and medical countermeasures to chemical, biological, radiological, and nuclear threats which also includes investments by the State of Texas Emerging Technology Fund, commercial, and academic partners.

The Center will catalyze research, facilitate development, ensure domestic manufacturing capacity, enable product FDA approval, and mentor the next generation of public health professionals through education, training, and outreach.

The Texas A&M University System (TAMUS) is the prime contractor for a team of leading academic, non-profit, and commercial institutions that provide the Center’s personnel, infrastructure, products, intellectual property, and commitment to U.S.-based advanced development and manufacturing. The team’s expertise is comprehensive – including early process development, Good Laboratory Practices (GLP), pivotal animal rule efficacy studies, Good Manufacturing Practices (GMP), biomanufacturing, and human clinical trials. All aspects of the program are supported by national leaders in regulatory strategy.

This highly integrated team is pioneering, developing, and utilizing rapid and flexible approaches to shepherd vaccines and therapeutics from proof-of-concept through licensure.  Ultimately, the Center will enhance national security by bolstering the United States' response capability to any attack or threat, including (but not limited to) influenza, as well as previously unrecognized, naturally occurring emerging infectious diseases that will broadly impact national and global health.

 

two sicentists working in a lab